Abstract
Background Management of chronic pain is limited by inadequate effectiveness and undesirable safety profiles of currently available medi cations. There is growing evidence that adenosine (A1, A2A, A2B, A3) receptors can be promising therapeutic targets for treatment of chronic pain. A number of selective ligands for adenosine receptors have been introduced. Agents acting selectively at A1, A2A and A2B receptors have been effective in several preclinical animal models of pain and several have also entered into clinical development for neuropathic pain. Unfortunately, safety concerns related to significant cardiovascular side effects caused by systemic administration of some of these agents limited further development. In contrast, systemic administration of certain selective A3 receptor agonists is not associated with cardiac or hemodynamic side effects, making the A3
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call